Halozyme Announces Upcoming Data Presentations at American Society of Hematology Annual Meeting For APOLLO and ANDROMEDA Phase 3 Studies By Janssen Evaluating Subcutaneous Daratumumab Utilizing ENHANZE®
Halozyme Therapeutics (NASDAQ: HALO) has announced that key studies sponsored by Janssen Research & Development will be presented at the American Society of Hematology (ASH) Annual Meeting from December 5-8, 2020. The Phase 3 APOLLO study will feature an oral presentation on December 6 at 3:00 p.m. ET, discussing subcutaneous daratumumab with pomalidomide and dexamethasone in multiple myeloma patients. The ANDROMEDA study results will be presented on December 7, also in an oral format, along with four additional poster presentations.
- Upcoming presentations at ASH Annual Meeting highlight significant research on SC daratumumab.
- APOLLO and ANDROMEDA studies show potential for improved treatment options in multiple myeloma and AL amyloidosis.
- None.
SAN DIEGO, Nov. 5, 2020 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that studies sponsored by Janssen Research & Development, LLC (Janssen) evaluating subcutaneous (SC) daratumumab utilizing ENHANZE® will be the subject of presentations at the upcoming American Society of Hematology (ASH) Annual Meeting and Exposition taking place virtually December 5-8, 2020.
Primary data from the Phase 3 APOLLO study of SC daratumumab in combination with pomalidomide and dexamethasone (D-Pd) in patients with multiple myeloma who have received one or more prior lines of therapy (Abstract #412) will be the subject of an oral presentation and official ASH Press Program (Sunday, December 6 3:00 p.m. ET).
Results from the Phase 3 ANDROMEDA study of SC daratumumab in combination with bortezomib, cyclophosphamide and dexamethasone (D-VCd) in patients with light chain AL amyloidosis (Abstract #552) will be the subject of an oral presentation (Monday, December 7 11:15 a.m. ET). The ANDROMEDA study will also be the subject of four poster presentations (Abstracts #1392, #1640, #1409 and #2305).
About Halozyme
Halozyme is a biopharmaceutical company bringing disruptive solutions to significantly improve patient experiences and outcomes for emerging and established therapies. Halozyme advises and supports its biopharmaceutical partners in key aspects of new drug development with the goal of improving patients' lives while helping its partners achieve global commercial success. As the innovators of the ENHANZE® technology, which can reduce hours-long treatments to a matter of minutes, Halozyme's commercially-validated solution has positively impacted more than 400,000 patient lives via five commercialized products across more than 100 global markets. Halozyme and its world-class partners are currently advancing multiple therapeutic programs intended to deliver innovative therapies, with the potential to improve the lives of patients around the globe. Halozyme's proprietary enzyme rHuPH20 forms the basis of the ENHANZE® technology and is used to facilitate the delivery of injected drugs and fluids, potentially reducing the treatment burden of other drugs to patients. Halozyme has licensed its ENHANZE® technology to leading pharmaceutical and biotechnology companies including Roche, Baxalta, Pfizer, Janssen, AbbVie, Lilly, Bristol-Myers Squibb, Alexion and argenx. Halozyme derives revenues from these collaborations in the form of milestones and royalties as the Company's partners make progress developing and commercializing their products being developed with ENHANZE®. Halozyme is headquartered in San Diego. For more information visit www.halozyme.com.
Halozyme Safe Harbor Statement
In addition to historical information, the statements set forth above include forward-looking statements including, without limitation, statements concerning the possible activity, benefits and attributes of ENHANZE®, the possible method of action of ENHANZE®, its potential application to aid in the dispersion and absorption of other injected therapeutic drugs, and statements concerning certain other potential benefits of ENHANZE® including facilitating more rapid delivery of injectable medications through subcutaneous delivery. These forward-looking statements also include statements regarding the product development efforts of Halozyme's ENHANZE® partner. These forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. The forward-looking statements are typically, but not always, identified through use of the words "believe," "enable," "may," "will," "could," "intends," "estimate," "anticipate," "plan," "predict," "probable," "potential," "possible," "should," "continue," and other words of similar meaning. Actual results could differ materially from the expectations contained in forward-looking statements as a result of several factors, including uncertainties concerning whether collaborative products are ultimately developed, approved or commercialized, unexpected expenditures and costs, unexpected results or delays in development and regulatory review including any potential delays caused by the current COVID-19 global pandemic, unexpected regulatory approval requirements, unexpected adverse events or patient outcomes, and competitive conditions. These and other factors that may result in differences are discussed in greater detail in Halozyme's most recent Annual and Quarterly Reports filed with the Securities and Exchange Commission. Except as required by law, Halozyme undertakes no duty to update forward-looking statements to reflect events after the date of this release.
Contact:
Al Kildani
Vice President, Investor Relations and Corporate Communications
858-704-8122
ir@halozyme.com
View original content to download multimedia:http://www.prnewswire.com/news-releases/halozyme-announces-upcoming-data-presentations-at-american-society-of-hematology-annual-meeting-for-apollo-and-andromeda-phase-3-studies-by-janssen-evaluating-subcutaneous-daratumumab-utilizing-enhanze-301166975.html
SOURCE Halozyme Therapeutics, Inc.
FAQ
What will be presented at ASH Annual Meeting by Halozyme?
When are the presentations scheduled at the ASH Annual Meeting?
What is the importance of the APOLLO and ANDROMEDA studies?
Where can I find more information about Halozyme and its trials?
